Increased levels of an endogenous inhibitor of tissueplasminogen activator (t-PA) have been thought to relate to the genesis of acute myocardial ischemia. To examine the role of the rapid inhibitor of t-PA, plasma samples were analyzed from 75 patients with chest pain syndrome undergoing coronary angiography (mean age 57 years), 24 patients with clinically documented coronary artery disease (unstable angina, positive exercise stress test or previous history of myocardial infarction; mean age 58 years) and 15 young normal subjects (mean age 26 years). Plasma t-PA inhibitor levelswere similar in age-matched patients regardless of the absence or presence (and degree) of coronary artery disease. Plasma t·PA inhibitor levels correlated significantly with age (r -0.46, p < Tissue plasminogen activator (t-PA) has been shown to be a promi sing agent in the treatment of coronary artery thrombosis associated with acute myocardial infarction (I). A rapid inhibitor of t-PA has also been identified in human plasma (2) (3) (4) (5) , and plasma levels of this inhibitor have recentl y been reported to be increased in patients with coronary artery disease (6) (7) (8) . Increased plasma levels of the inhibitor of t-PA might have implications for the pathogenesis of coronary artery disea se , because impaired fibrinol ysis has been claimed to participate in the development (8.9) and genesis of clinical states associated with intravascular thrombosis. In the present investigation, we measured plasma 0.005), suggesting an age-dependent decrease in fibrinolytic activity. Plasma t·PA inhibitor levels also correlated significantly with serum triglyceride levels (r -0.60, p < 0.001), but not with coronary risk factors such as serum cholesterol, diabetes, hypertension , serum uric acid levels or body weight.
Association of high levels of inhibitor of t·PA with hypertriglyceridemia may be of importance in the development of coronary thrombosis, especially in elderly patients. Nonetheless, this study does not suggest a pathogenic role of t·PA inhibitor in coronary atherosclerosis. (J Am Coil Cardiol 1987; 9:263-8) t-PA inhibitor levels in a large number of subjects and correlated the levels of the inhibitor with the existence and extent of coronary artery disease as well as with coronary risk factors .
Methods
Subjects. Peripheral blood samples from 75 patient s (74 men and I woman, aged 33 to 85 years) with a chest pain syndrome who were undergoing diagnostic coronary angiography were assayed for tissue plasminogen activator (t-PA) inhibitor levels. The extent of coronary atherosclerosis in these subjects was graded on a scale of 0 to 3 depending on the number of vessels with a luminal diameter reduction of greater than 50%.
Plasma samples from 24 outpatients (aged 34 to 72 years) with clinically documented co ronary artery disease (previous history of myocardial infarction, positive exercise stress test or unstable angina ) were also assayed for the inhibitor levels. Plasma samples from 5 pediatric subjects (aged 5 to I7 years) and from 10 health y, normal laboratory personnel (aged 25 to 54 years) were also examined. Measurement of the inhibitor of tissue-plasminogen activator (t-PA). Peripheral venous blood samples were collected from all subjects in trisodium citrate only between 8:00 and 9:00 A .M. becau se diurnal variation has been described in the plasma levels of the inhibitor (10) . Blood was centrifuged at 4°C for 20 minutes at 1,500 g and plasma stored at -70°C. The plasma levels of the inhibitor were measured by an amidol ytic assay using purified t-PA and a chromogenic substrate (3, 10) . In brief. t-PA is added to multiple dilution s of plasma , and residual t-PA activity is subsequently determined using the plasmin substrate p-ValLeu-Lys-p-nitroan iline (5 2251 ), a gift from Kabi-Vitrum AB, Stockholm . Plasm in inhibitors such as alpha s-antiplasmin and alpha--macroglobulin are destroyed by acidification. One unit of the inhibitor is the amount inhibiting one unit of t-PA in this system. Coronary risk factors . Serum levels of total chole sterol, triglycerides and uric acid were measured by standard enzymatic method s after a 12 hour fast in the 75 patient s undergoing cardiac catheterization . The subjects were considered hyperten sive if the supine diastolic blood pressure was greater than 90 mm Hg on at least two occasions. Smoking history, expre ssed as pack-years. was obtained by personal interview with the patients. Patients were considered to have diabetes mellitu s if they were taking hypoglycemic agent s or if they had been previously told they were diabetic and were treated with dietary control.
Statistical analysis. Group differences between patients with and without significant coronary atherosclero sis were tested for significance by the nonparametric Kruskal -Walli s one-way analysis of variance and the Mann-Whitney test. The relation between plasma levels of the t-PA inhibitor and coronary risk factors was examined by conventional linear regression analysis.
Results
Plasma tissue-plasminogen activator (t-PA) inhibitor levels. The data on the 75 patients with angiographic evidence of absence or presence (as well as extent) of coronary athero sclerosis are presented in Table I . In these subgroups of patients with similar age but different extent of disease , t-PA inhibitor levels were not significantly different (p = NS). Serum levels of triglyceride, total cholesterol and uric acid as well as smoking pattern and prevalence of hypertension and diabetes mellitu s were similar in these subgroups of patients. The t-PA inhibitor levels in patients with clinical evidence of coronary artery disease (3.02 ± 1.51 units/ml , mean ± SD) were also in the same range as in the patients undergoing coronary angiograph y (Fig. I) . However, compared with levels in healthy, normal laboratory personnel (mean 0.99 ± 0.64 units/ml) and pediatric subjects (mean 1.17 ± 0.95 units/rnl), t-PA inhibitor levels in patients with clinically or angiographically documented coronary disease were significantly (p < 0.02) increased .
Plasma tissue-plasminogen activator (t·PA) inhibitor levels and coronary risk factors. The t-PA inhibitor levels correlated significantly with age ( Fig. 2) (r -0 .46, P < 0.005 ), rising in older patients and were also correlated significantly with serum triglyceride levels ( Fig. 3 ) (r - 
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0.60, P < 0.00 1). There was, however, no correlation between t-PA inhibitor levels and the serum concentrations of total cholesterol (Fig. 4) , uric acid, patients' body weight, history of smoking, presence of hypertension or diabetes mellitus. The mean plasma value of the t-PA inhibitor was 2.57 ± 1.47 units/ml in normotensive subjects and 2.14 ± 1.44 units/ml in hypertensive subjects (p = NS). It was 2.32 ± 1.47 units/ml in patients without diabetes mellitus and 1.96 ± 1.41 units/ml in patients with diabetes mellitus (p = NS).
Discussion
Age and t-PA inhibitor. The results of our study demonstrate that patients with coronary artery disease have higher plasma levels of tissue-plasminogen activator (t-PA) inhibitor than do young normal, healthy subjects, and that the plasma levels of the inhibitor do not vary with the extent of the disease (7) . Furthermore. we found no significant difference between age-matched patients with chest pain without significant coronary disease and others with signif- icant disease relative to the plasma levels of t-PA inhibitor. These data strongly suggest that high levels oft-PA inhibitor are not primaril y associated with coronary disease. Nevertheless, we found a significant correlation between the plasma levels of t-PA inhibitor and age of the subjects. Because the patients with coronary artery disease are generally older than those without disease , age is probabl y a contributory factor to the difference in t-PA inhibitor levels observed previously. An influence of age on defective fibrinolysis as determined by the dilute blood clot lysis time has earlier been reported , but the results are conflicting. Chakrabarti et al. (9) initially described an increase in fibrinolytic activity with age in patients with coronary artery disease. However , these investigators ( I I) later found reduction in fibrinolytic activity after analysis of a large number of such patients. The clot lysis time used by these investigators is nonspecific and dependent on both plasminogen activators and various fibrinolysis inhibitors .
Serum triglycerides and tissue-plasminogen activator (t-PA) inhibitor. Another factor that may have contributed to the increased plasma levels of t-PA inhibitor in our pa- 
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Sel"um total-enole.terol (mg/dl) tients undergoing coronary angiography is the significant prevalence of hypertriglyceridemia. The correlation between high levels of triglycerides and t-PA inhibitor found in the present investigation confirms similar observations made previously by us (10) and recently by Hamsten et al. (12) . Although our results suggest that t-PA inhibitor is not of pathogenetic importance for coronary artherosclerosis, it is possible that hypertriglyceridemia may contribute to coronary thrombosis by inducing an increase in t-PA inhibitor levels, especially in elderly patients. That an increase in t-PA inhibitor may be secondary to the increase in triglycerides is favored by the demonstrated association of dietary regulation of triglycerides and increased fibrinolytic activity (13) , which may be due to a reduction in t-PA inhibitor levels. At present, however, we cannot exclude a common factor, such as increased levels of catecholamines (12), which may cause elevation of both serum triglycerides and t-PA inhibitor levels, particularly in patients under stress. Nonetheless, coronary thrombosis may relate to reduced fibrinolytic activity, which has been found in patients with coronary artery disease who later died (14) . Reduced fibrinolytic activity has also been associated with graft occlusion in patients undergoing aortocoronary bypass surgery (15) . Tissue-plasminogen activator (t-PA) inhibitor and fibrinolysis. Inhibitor of t-PA is probably produced by endothelial cells (16) as well as in platelets (17) . Increased levels of this inhibitor were found in patients with the adult respiratory distress syndrome after trauma and sepsis (18) , possibly related to endotoxin-induced release of t-PA inhibitor from the endothelial cells (5) . A high level of t-PA inhibitor seems also to be responsible for the impaired fibrinolytic response to venous occlusion found in patients with deep venous thrombosis (19) , related probably to rapid inactivation of the released t-PA by the inhibitor. The t-PA inhibitor rapidly forms a stable, inactive complex with t-PA (20) and this mechanism may be of importance for delayed fibrin degradation and development of thrombosis. A protraction of whole blood and plasma clot lysis in patients with naturally occurring high levels of t-PA inhibitor which suggests a pathophysiologic significance of t-PA inhibitor in fibrinolysis and thrombolysis, was recently demonstrated (21) . An in vivo effect of t-PA inhibitor on fibrin degradation and thrombolysis, however. has yet to be proved. Interestingly, an identical impaired response to fibrinolytic stimulus found in patients with thrombosis and high levels of the t-PA inhibitor (19) was demonstrated in patients with hypertriglyceridemia (22) , further suggesting a connection between triglycerides, t-PA inhibitor, and thrombosis. Normal values of tissue-plasminogen activator (t-PA) inhibitor. An international standard for t-PA inhibitor is not yet available, and the levels obtained in healthy, normal subjects differ among various laboratories. Mean values of 1.5 ± 0.7 (7), 0.46 ± 0.50 (8) and 0.7 ± 0.7 units/ml (23) have been reported. Plasma t-PA levels reported in patients with coronary artery disease range from 0.80 ± I. 19 (8) to 3.1 ± I. 2 units/ml (7). These differences can partly be explained by variations in age and triglyceride levels, and also by the diurnal change in the inhibitor levels (10). They could also be due to lack of uniformity in assays for measurement of the inhibitor; for example, it has been reported that the rate of inhibition of t-PA increases with the amount of t-PA added to plasma (24) .
Conclusions. Hypertriglyceridemia, especially in elderly patients with coronary artery disease, is associated with increased plasma levels oft-PA inhibitor. This increase in the t-PA inhibitor levels might be of importance in the evolution of coronary thrombosis in these patients and could possibly be involved in the impaired response to t-PA treatment of coronary thrombosis in some patients. The fact that no difference in t-PA inhibitor levels was found between age-matched patients with and without coronary artery disease (and variable extent) speaks against, but does not exclude, an important role for t-PA in the development of coronary atherosclerosis.
